Ovarian Cancer
PEACOCC: Pembrolizumab in Advanced Clear Cell Gynecological Cancer
Pembrolizumab demonstrated clinical benefit in heavily pretreated advanced CCGC with a tolerable safety profile. Further evaluation in a randomized trial is warranted.
LARA: Pembrolizumab plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma
Pembrolizumab plus lenvatinib demonstrated promising anti-tumor activity with an objective response rate of 40% at 24 weeks in patients with recurrent gynaecological clear cell carcinoma.
GOG 3026: Ribociclib Plus Letrozole in Recurrent Low-Grade Serous Ovarian Carcinoma
ROSELLA (GOG-3073/ENGOT-ov72): Relacorilant plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.
NRG-GY023: Durvalumab, Olaparib, and Cediranib vs Chemotherapy in Platinum-Resistant Ovarian Cancer with Prior Bevacizumab
The addition of durvalumab with olaparib and cediranib did not improve PFS in platinum-resistant ovarian cancer patients with prior bevacizumab exposure.
CHIPOR: Secondary Debulking and HIPEC in Platinum-Sensitive Recurrent Ovarian Cancer
HIPEC combined with cytoreductive surgery significantly improved overall survival and progression-free survival in recurrent ovarian cancer
Management of STIC in Patients Undergoing RRSO
Management of STIC
Oncologic outcomes of incidental serous tubal intraepithelial